AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...
At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.
News Medical on MSN12h
Dual-target drug may lead to new treatment approach for breast cancer patientsResearchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...
GlobalData on MSN21h
Health Canada approves MSD’s Keytruda for NSCLC stagesHealth Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...
Wednesday's market has seen significant movements in various stocks, with some notable fluctuations in the mega-cap and large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback